PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models
summary
The gist
Anti-cancer drug response prediction (DRP) is critically important for precision oncology and therapeutic development These studies generated data for improving and evaluating DRP models…
In short
The study generated new drug screening data from patient-derived organoids (PDOs) to improve AI models that predict drug response. Researchers tested different ways to train models using existing cell line (CCL) and PDO data, finding that combining both datasets and using transfer learning generally improved prediction accuracy for PDO responses.
Key concepts
- Anti-cancer Drug Response Prediction (DRP)
- This is the goal of the research: building AI models that can accurately predict how a specific drug will affect a patient's tumor, using molecular data from organoids (PDOs). This is crucial for precision oncology.
- Cancer Cell Lines (CCLs) vs. Patient-Derived Organoids (PDOs)
- CCLs are immortalized cell lines used in existing models, while PDOs are grown from actual patient tumors. The study aimed to see if knowledge learned from the more abundant CCL data could be effectively transferred to predict responses in the more biologically relevant PDOs.
- Transfer Learning
- This is a technique where a model first learns general patterns from a large, well-studied dataset (like CCL data) and then adapts those learned patterns to a smaller, specific dataset (like PDO data). The study found this method often boosted performance but risked 'forgetting' the initial general knowledge.
Terminology used across episodes
This episode discusses
- PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models · Paper Radio
The paper
PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models · Read on arXiv
Yitan Zhu, Kaitlyn Marlor, Vincent Lavelle, Thomas S Brettin, Matteo Sacco, Costanza Siniscalchi, Henry W Raeder, Michael Ryan Weil
Division of Data Science and Learning, Argonne National Laboratory · Computing, Environment and Life Sciences, Argonne National Laboratory Department of Medicine, Section of Hematology/Oncology, University of Chicago Department of Human Genetics, University of Chicago Cancer Research Technology Program Cancer Data Science Initiatives at Frederick National Laboratory for Cancer Research Department of Computer Science The University of Chicago
Anti-cancer drug response prediction (DRP) is critically important for precision oncology and therapeutic development. Currently, most DRP models are developed using drug screening data from immortalized cancer cell lines, which can differ substantially from patient tumors at the genomic and molecular levels, even though patient tumor response is the ultimate prediction target. To help bridge this gap and bring DRP models closer to their intended clinical application, we conducted four drug screening studies using patient-derived organoids (PDOs), which more faithfully recapitulate patient tumors than immortalized cell lines. These studies generated data for improving and evaluating DRP models, including multi-omics profiles of PDO lines, drug feature data, and treatment response measurements. Using these data, we retrained and evaluated multiple publicly available DRP models under three model-building scenarios: training models using cell line data only, training models using combined cell line and PDO data, and pretraining models on cell line data followed by fine-tuning on PDO data. We then evaluated and compared model prediction performance on PDOs across these analysis scenarios. In addition, we also assessed the consistency of drug screening viability data generated by different laboratories using different assay technologies and/or experimental protocols.
Transcript
Introduction to the show: ident: Genomics Radio. Generated commentary on the latest computational biology and genomics papers.
Ines: We're looking at the paper: "PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models".
Marcus: Here's the gist of the paper. Anti-cancer drug response prediction (DRP) is critically important for precision oncology and therapeutic development These studies generated data for improving and evaluating DRP models, including multi-omics profiles of PDO lines, drug feature data, and treatment response measurements By systematically evaluating multiple model architectures and learning strategies across independently generated PDO datasets, the work characterizes the extent to which knowledge learned from large-scale CCL datasets transfers to PDOs and whether limited PDO data can improve predictive performance in the target domain Data Generation Strategy The research addressed a gap between existing DRP models developed using immortalized cancer cell lines (CCLs) and patient tumors by generating new drug screening data using patient-derived organoids (PDOs).
Ines: Four drug screening studies spanning colorectal cancer, head and neck cancer, and sarcoma PDOs were conducted to produce matched treatment response measurements and molecular profiles across multiple experimental platforms and assay protocols Three of these studies were designed with overlapping PDOs and compounds, enabling direct comparison of drug response measurements generated independently using different screening technologies and experimental procedures.
Marcus: Model Training Scenarios The study evaluated six publicly available DRP models under three learning strategies to assess how CCL and PDO data can be used for predicting PDO drug response.
Ines: These scenarios included: 1.
Paper summary: Ines: So, we're talking about this paper called "PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models". It's focused on making drug response prediction more accurate for actual patient tumors.
Marcus: Exactly. The core idea here is that most of the drug response prediction models out there are trained on cancer cell lines, which can be quite different from what we actually see in a patient's tumor at the genomic and molecular level <ref:2611.15769#pg2>.
Ines: Right. The paper claims they generated new data using patient-derived organoids, or PDOs, to bridge that gap between cell lines and tumors eight <ref:2611.15769#pg3,gap between cell lines and>. They set out to see how knowledge from the large cell line datasets transfers to these PDOs and if adding just a little bit of PDO data can actually improve the prediction performance in the real target domain.
Yuki: From a population genetics standpoint, that makes sense. We know that immortalized cell lines are just one snapshot, and patient tumors have all those different biological histories <ref:2611.15769#pg3>. I'm curious how much of that transfer learning actually works in practice for these complex systems.
Marcus: Well, they tested six different existing drug response prediction models using three different ways to train them. They looked at training models only on the large cell line data, then with a mix of cell line and some PDO data, and finally pretraining on the cell lines and then fine-tuning with the PDO data <ref:2611.15769#pg3>.
Ines: And they used different ways to check their results too, like random partitioning for cross validation, which is pretty standard, and cancer-blind partitioning for a stricter test of how well the model generalizes across different patient cases <ref:2611.15769#pg3>.
Yuki: That brings up a question about the sample size. When they talk about limited PDO data improving performance, how much is 'limited' actually limited in terms of what you can support genetically?
Marcus: The paper found that incorporating even a portion of the PDO data into the training improved the prediction performance, showing an increase in model-average R squared for PDO prediction across various datasets <ref:2611.15769#pg3>.
Ines: And they also looked at transfer learning—pretraining on cell lines and then fine-tuning on PDO data—and that generally improved the prediction performance compared to training them jointly when the PDO domain data was only a small fraction of the total training set <ref:2611.15769#pg3>.
Yuki: That sounds like a promising direction for building models that are more robust to those experimental differences between culture and in vivo settings. But what about the downside of that transfer learning? Does it introduce new problems?
Marcus: Yes, the authors mentioned that this transfer learning approach came at the cost of forgetting previously learned patterns from the cell lines <ref:2611.15769#pg3>. So you get better performance on PDOs, but you might lose some of what you learned about those cell lines.
Ines: That's a trade-off we see all the time in machine learning, right? We want to adapt to new data without completely erasing the valuable knowledge from the initial training set. But how robust are these findings when you look at specific datasets?
Yuki: I'm interested in those specifics. They mentioned that prediction performance on one particular dataset, the IMPROVE dataset two was consistently the lowest among all four drug screening studies <ref:2611.15769#pg3>.
Marcus: And they even found negative r squared values in some cases there <ref:2611.15769#pg3>. The authors attributed that to an issue with insufficient mixing of the cell culture medium, which is a very concrete experimental detail <ref:2611.15769#pg3>.
Ines: That’s a fair caveat. It shows that even with good methodology, biological variability and technical noise in the data collection process can still cause significant issues for the models <ref:2611.15769#pg3>.
Yuki: So, what does this mean for us looking at the broader landscape of drug response prediction? Does this suggest that focusing only on cell lines is fundamentally limiting our ability to predict patient outcomes?
Marcus: It suggests that while cell line data is an essential starting point because it's reproducible and easy to get large amounts of, it clearly doesn't capture everything about patient tumors <ref:2611.15769#pg2>. The utility of these new PDO datasets is that they help us develop and evaluate DRP models that are actually closer to predicting patient response eight <ref:2611.15769#pg3>.
Ines: So, the paper’s main contribution is demonstrating the utility of these newly generated datasets for developing and evaluating DRP models for PDO drug response prediction <ref:2611.15769#pg3>. It moves us from just using cell lines to testing how much we can learn from patient-like samples.
Yuki: I think it means that expanding and harmonizing these PDO drug screening datasets is an important step toward building DRP models that actually work for patients <ref:2611.15769#pg3>. We need more data like this to understand the true complexity of cancer response across different biological backgrounds.
Marcus: Right. And alongside that, we still need computational methods that explicitly account for those systematic differences between experimental platforms and drug response distributions <ref:2611.15769#pg3>. That's where the next challenge lies.
Conclusion: Ines: So, we've been looking at this paper about using patient derived organoids or PDOs to help train and test drug response prediction models.
Marcus: Yeah, the title is "PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models." It’s about taking those organoid data points and seeing if they actually make a difference in predicting how a real tumor will react to medicine.
Ines: Basically, the authors are showing how incorporating this patient-like data into existing cell line prediction models actually improves the performance numbers on PDO responses.
Marcus: They tested six different AI models and three ways of training them—just cell line data, a mix with some PDO data, or pretraining on cell lines and then fine tuning on the organoid stuff.
Yuki: From a population genetics view, this is interesting because it shows whether that limited set of patient samples can actually support a better prediction for the whole group of patients.
Ines: And they found that adding even a small amount of PDO data improves those model average R squared values across different datasets.
Marcus: Transfer learning, where you train on cell lines first and then fine tune with PDO data, generally beats just training everything together when the organoid data is only a small piece of the total training set.
Yuki: But they did flag that this transfer learning comes with a cost—the model starts forgetting some of those initial drug response patterns it learned from just the cell lines.
Ines: That trade-off between better accuracy and losing old knowledge is something we always have to think about in these systems.
Marcus: And they also found some specific limitations, like one dataset showed negative r squared values because the cell culture medium wasn't mixed enough, which shows how much technical stuff can mess with the data.
Yuki: So it sounds like the big implication is that we need to expand and harmonize these PDO screening datasets if we want DRP models that actually work for patients, but we also still need better ways to handle those experimental differences.
Ines: Exactly. So what does this mean for the world in terms of precision oncology?
More episodes
- 2610.33881-Sensorimotor behavior from an untrained brain-and-nerve-cord connectome
- 2610.40344-Morphological Features of Murine Pulmonary Arterial Networks for Diagnosing Vascular Disease
- Daily Summary for 2026-11-19
- 2609.10193-Are You Learning Biological Signal or Shortcuts? Auditing and Mitigating Bias in Protein-Protein Interaction Datasets
- 2610.38236-Generative discovery of chemical reaction networks
- 2507.11176-An Interpretable AI framework Quantifying Traditional Chinese Medicine Principles Towards Enhancing and Integrating with Modern Biomedicine
- The day in conversation for 2026-11-19
- Daily Summary for 2026-11-19
- 2504.03590-Towards a Unified Framework for Determining Conformational Ensembles of Disordered Proteins
- 2603.15217-A multiscale discrete-to-continuum framework for structured population models